

Special Issue

Advances in Research in Sarcopenia

Message from the Guest Editor

We invite original research articles, comprehensive reviews, and clinical studies for this Special Issue titled "Advances in Research in Sarcopenia." This collection aims to showcase cutting-edge investigations into sarcopenia's multifaceted nature, encompassing primary age-related muscle decline and secondary sarcopenia arising from chronic diseases, metabolic disorders, and systemic conditions. We welcome work on molecular mechanisms—epigenetics, mitochondria, inflammation, oxidative stress, hormonal changes—and the bidirectional links between sarcopenia and metabolic disorders (diabetes, obesity, liver, renal, cardiovascular disease). Studies on muscle wasting driven by pathogens, chronic infections, or systemic inflammation are encouraged. Topics include novel biomarkers, advanced imaging, therapeutics, and prevention. We seek manuscripts on sarcopenia in cancer cachexia, CKD, COPD, chronic liver disease, and other debilitating conditions. Translational research bridging bench and bedside is especially welcome. Join us in advancing our understanding of sarcopenia to improve patient outcomes and quality of life across diverse populations.

Guest Editor

Prof. Dr. Claudio Cabello-Verrugio

Center for Research on Pandemic Resilience, Faculty of Life Sciences,
Universidad Andres Bello, Santiago, Chile

Deadline for manuscript submissions

31 August 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/268382

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).